Mydekla 60Mg 28 Tablets is an antiviral medicine used along with sofosbuvir, with or without ribavirin, to treat chronic hepatitis C viral genotype 1 or 3 infection. It is a serious infection caused by the hepatitis C virus. It is a contagious infection that spreads from person to person and affects the liver. Mydekla 60Mg 28 Tablets is only used in treating the infection. It does not cure or prevent further liver complications.

Mydekla 60Mg 28 Tablets contains Daclatasvir, which belongs to the class of hepatitis C virus (HCV) NS5A inhibitors. It works by blocking the activity of the hepatitis C virus in the liver cells. This causes viral DNA termination and reduces the amount of hepatitis C virus in the body.

Mydekla 60Mg 28 Tablets may cause certain side effects such as headache, fatigue, weakness, confusion, chest pain, nausea, diarrhoea, shortness of breath, dizziness and lightheadedness. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. Use it as suggested by your doctor. Your doctor will decide the duration of the medicine based on your health condition.

Mydekla 60Mg 28 Tablets should be avoided if you are allergic to it. If you are pregnant or breastfeeding, inform your doctor before starting treatment with this medicine. Mydekla 60Mg 28 Tablets is not recommended for children below 18 years of age as efficacy and safety have not been established. Inform your doctor if you have any underlying conditions like hepatitis B virus infection, liver cirrhosis, nephrotoxicity, liver transplant, heart problem, kidney problems, or HIV infection, as it may cause serious side effects. Mydekla 60Mg 28 Tablets may cause hepatitis B infection reactivation and bradycardia (slow heart rate) in some patients. Hence, patients should be monitored carefully for any changes.

Mydekla 60Mg 28 Tablets contains Daclatasvir, which belongs to the class of hepatitis C virus (HCV) NS5A inhibitors. It works by blocking the activity of the hepatitis C virus in the liver cells. This causes viral DNA termination and, therefore, reduces the amount of hepatitis C virus in the body.

Mydekla 60Mg 28 Tablets should be avoided if you are allergic to it. If you are pregnant or breastfeeding, inform your doctor before starting treatment with this medicine. Mydekla 60Mg 28 Tablets is not recommended for children below 18 years of age as efficacy and safety have not been established. Inform your doctor if you have any underlying conditions like hepatitis B virus infection, liver cirrhosis, nephrotoxicity, liver transplant, heart problem, other kidney problems, or HIV infection, as it may cause serious side effects. Mydekla 60Mg 28 Tablets may cause hepatitis B infection reactivation and bradycardia in some patients. Hence, patients should be monitored carefully for any changes.

• Close monitoring of liver and kidney function tests is required while on treatment with Mydekla 60Mg 28 Tablets to monitor liver and kidney functions.
• Sudden withdrawal of Mydekla 60Mg 28 Tablets should be avoided as it can cause severe acute exacerbations of hepatitis or other serious side effects.